您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > BLU-554
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BLU-554
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BLU-554图片
CAS NO:1707289-21-1
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
BLU-554 (BLU-554) 是一种有效的、高选择性和口服活性的成纤维细胞生长因子受体 4 (FGFR4) 抑制剂,IC50 为 5 nM。 BLU-554 在依赖 FGFR4 信号传导的肝细胞癌 (HCC) 模型中具有显着的抗肿瘤活性。
Cas No.1707289-21-1
别名BLU-554
Canonical SMILESC=CC(N[C@@H]1[C@H](NC2=NC=C3C=C(C4=C(Cl)C(OC)=CC(OC)=C4Cl)C=CC3=N2)COCC1)=O
分子式C24H24Cl2N4O4
分子量503.38
溶解度DMSO : ≥ 25 mg/mL (49.66 mM)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor.

Fibroblast growth factor receptor 4 (FGFR-4) is a protein that in humans is encoded by the FGFR-4 gene. This protein is a member of the fibroblast growth factor receptor family, where amino acid sequence was highly conserved between members throughout evolution. FGFR family members 1-4 differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. The genomic organization of the FGFR-4 gene encompasses 18 exons. Although alternative splicing has been observed, there is no evidence that the C-terminal half of the Iglll domain of this protein varies between three alternate forms, as indicated for FGFR 1-3[1].

References:
[1]. Neil Bifulco, et al. Inhibitors of the fibroblast growth factor receptor. PCT Int. Appl. (2015), WO 2015061572 A1 20150430.